Skip to Content
Merck
  • SCFAs switch stem cell fate through HDAC inhibition to improve barrier integrity in 3D intestinal organoids from patients with obesity.

SCFAs switch stem cell fate through HDAC inhibition to improve barrier integrity in 3D intestinal organoids from patients with obesity.

iScience (2023-12-21)
Mona Farhadipour, Kaline Arnauts, Mathias Clarysse, Theo Thijs, Kathrin Liszt, Bart Van der Schueren, Laurens J Ceulemans, Ellen Deleus, Matthias Lannoo, Marc Ferrante, Inge Depoortere
ABSTRACT

Stem cells are a keystone of intestinal homeostasis, but their function could be shifted during energy imbalance or by crosstalk with microbial metabolites in the stem cell niche. This study reports the effect of obesity and microbiota-derived short-chain fatty acids (SCFAs) on intestinal stem cell (ISC) fate in human crypt-derived intestinal organoids (enteroids). ISC fate decision was impaired in obesity, resulting in smaller enteroids with less outward protruding crypts. Our key finding is that SCFAs switch ISC commitment to the absorptive enterocytes, resulting in reduced intestinal permeability in obese enteroids. Mechanistically, SCFAs act as HDAC inhibitors in stem cells to enhance Notch signaling, resulting in transcriptional activation of the Notch target gene HES1 to promote enterocyte differentiation. In summary, targeted reprogramming of ISC fate, using HDAC inhibitors, may represent a potential, robust therapeutic strategy to improve gut integrity in obesity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
SB 202190, ≥98% (HPLC)
Sigma-Aldrich
Y-27632 dihydrochloride, ≥98% (HPLC)
Sigma-Aldrich
GPR43 (FFA2) Agonist, The GPR43 (FFA2) Agonist controls the biological activity of GPR43. This small molecule/inhibitor is primarily used for Biochemicals applications.
Sigma-Aldrich
CHIR99021, ≥98% (HPLC)
Sigma-Aldrich
Sodium butyrate, ≥98.5% (GC)
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
SAHA, ≥98% (HPLC)